Poseida Therapeutics, Inc. - PSTX STOCK NEWS

Poseida Therapeutics (PSTX) announced its participation in the Society for Immunotherapy of Cancer Annual Meeting, occurring from November 8-12, 2022. The company will present a poster detailing the ongoing Phase 1 clinical trial of P-MUC1C-ALLO1, aiming to treat advanced epithelial-derived solid tumors. This trial evaluates the safety, tolerability, and preliminary efficacy of P-MUC1C-ALLO1 and is expected to report initial data by early 2023. The presentation will be made by Dr. Jason Henry at the Boston Convention & Exhibition Center.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that CFO Johanna Mylet will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference, taking place in New York, NY from September 12-14, 2022. The on-demand session will be available starting at 7:00am ET on September 12. A replay will be accessible for 30 days post-presentation.

Poseida focuses on using proprietary genetic engineering technologies to develop next-generation cell and gene therapeutics aimed at curing diseases.

Poseida Therapeutics announced a strategic collaboration with Roche, securing a $110 million upfront payment to develop allogeneic CAR-T therapies for hematologic malignancies. The firm completed a public offering, generating $80.5 million, enhancing its capital structure. As of June 30, 2022, Poseida reported $142.6 million in cash, ensuring operational funding into mid-2024. Despite a net loss of $43 million for Q2 2022, the company remains focused on advancing its clinical pipeline with multiple ongoing CAR-T programs and expects initial clinical data from its trials by year-end.

Poseida Therapeutics (Nasdaq: PSTX) announced the closing of its underwritten public offering of 23 million shares at $3.50 each, generating gross proceeds of $80.5 million. This includes 3 million shares sold from the full exercise of underwriters' options. The offering was conducted under a shelf registration statement filed with the SEC. Joint book-running managers for the offering were Piper Sandler and William Blair & Company, with Cantor Fitzgerald & Co. and BTIG, LLC also participating.

Poseida Therapeutics, priced an underwritten public offering of 20 million shares at $3.50 per share, aiming to generate approximately $70 million in gross proceeds. The offering is expected to close on August 8, 2022, and will fund the development of their innovative gene therapy platforms. Underwriters, including Piper Sandler and William Blair, have a 30-day option to purchase an additional 3 million shares. The offering will be made under a shelf registration previously filed with the SEC.

Poseida Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: PSTX), has announced an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The offering is subject to market conditions and other factors, with no guarantee on its completion or terms. Piper Sandler and William Blair are leading the offering, which follows a previously filed shelf registration statement with the SEC. All shares sold will be offered by Poseida.

Poseida Therapeutics (Nasdaq: PSTX) has initiated an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered. The offering follows a previously filed Form S-3 shelf registration statement. Market conditions will influence the offering's completion and terms. Key underwriters include Piper Sandler and William Blair & Company, with additional managers from Cantor Fitzgerald and BTIG. The offering details will be available via SEC filings.

Poseida Therapeutics has announced a strategic collaboration with Roche to develop allogeneic CAR-T therapies aimed at hematologic malignancies. This partnership includes a $110 million upfront payment and potential future milestones valued up to $6 billion. Roche will lead late-stage development and commercialization, while Poseida will conduct initial Phase 1 studies. The agreement highlights the efforts to produce effective off-the-shelf cell therapies to meet significant patient needs. The collaboration's effectiveness is subject to HSR Act clearance.

Poseida Therapeutics (Nasdaq: PSTX) announced the appointment of George M. Church, Ph.D., to lead its newly established Gene Therapy Scientific Advisory Board (SAB). Dr. Church's extensive experience in genome engineering will guide Poseida's research in developing gene therapies for rare diseases, including ornithine transcarbamylase deficiency and Hemophilia A. This advisory board, alongside the Immuno-Oncology SAB, aims to enhance the company's innovations in gene editing and therapeutic solutions.